Study: GLP-1 Drugs Could Avert 6.6M Deaths, Free 32M Hectares by 2050

Widespread use of GLP-1 medications could prevent millions of deaths and repurpose vast tracts of farmland by 2050, according to a new study published in Nature Communications.

Researchers from the University of Aberdeen, the University of Edinburgh, and Scotland’s Rural College modeled two primary scenarios to determine how shifting global food demand might ripple through the environment and public health. In the first projection, GLP-1-mediated calorie reduction alone could result in 6.6 million avoided deaths annually by 2050 and free up 32 million hectares of natural land, NewsCord reported.

The study further suggests these benefits expand when medication is paired with dietary improvements. Combining treatment with a shift toward the EAT–Lancet diet could increase the projections to 7.7 million avoided deaths and 46 million hectares of land returned to nature, according to NewsCord. EnviroWireDaily reported slightly different figures for the combined scenario, estimating up to 7 million avoided deaths annually.

Freeing 32 million hectares could have a major environmental impact, an area slightly larger than Italy, EnviroWireDaily reported. However, the researchers cautioned that these outcomes are not guaranteed. Lower food demand among those taking the drugs could lead to cheaper global food prices, which might encourage increased consumption of unhealthy foods by untreated populations, partially offsetting the projected gains, NewsCord reported.

“Our findings suggest that these changes in food consumption could have consequences that extend beyond the individuals receiving treatment,” said Dr. Roslyn Henry, who led the study. She emphasized that the results should not be interpreted as placing environmental responsibility on people living with obesity.

The study frames obesity as a non-communicable disease, noting that global prevalence has nearly tripled since 1975.

While the World Health Organization issued its first recommendation supporting GLP-1 therapies in December 2025, global access remains limited. As of November 2025, approximately 12% of the U.S. adult population and 2.9% of adults in the U.K. reported using these medications, according to NewsCord.

“What we eat has consequences that extend beyond our own health,” said Professor Peter Alexander, linking those effects to agricultural production, international trade, and land management. The researchers argue that GLP-1 medicines should work alongside broader policy changes to make nutritious food more accessible, according to EnviroWireDaily. It remains unknown how international trade policies might shift to accommodate these changes in global food demand.

The University of Aberdeen continues to anchor global health and environmental research through its School of Medicine and Dentistry and School of Medical Sciences at the Foresterhill campus, one of Europe’s largest health campuses, which in 2024–25 secured £54.2 million in research grants and contracts.

Photo of author

Health Desk

Health Desk at Archyde.

Federal Judge Orders OSFATUN to Cover Radiotherapy Within 48 Hours

Us Magazine: Wealthy Shoppers Swap Puffers for $11 Heirloom Teddy Coats